6533b82afe1ef96bd128b9c8
RESEARCH PRODUCT
Outcome of LR-3 and LR-4 observations without arterial phase hyperenhancement at Gd-EOB-DTPA-enhanced MRI follow-up
Massimo MidiriGiuseppe SalvaggioGianvincenzo SparaciaLudovico La GruttaDomenica MatrangaEmanuele GrassedonioFrancesco AgnelloGiuseppe Lo ReDomenico AlbanoPatrizia ToiaGiuseppe MicciMassimo Galiasubject
Gadolinium DTPAGd-EOB-DTPA-enhanced MRILR-3Carcinoma HepatocellularLR-4business.industryLiver NeoplasmsGd-EOB-DTPAContrast MediaMagnetic Resonance Imaging030218 nuclear medicine & medical imagingSettore MED/01 - Statistica Medica03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisMedicineHumansLI-RADSRadiology Nuclear Medicine and imagingNuclear medicinebusinessSettore MED/36 - Diagnostica Per Immagini E RadioterapiaArterial phaseFollow-Up StudiesRetrospective Studiesdescription
Objective: The aim of this study was to retrospectively analyze the outcome of LR-3 and LR-4 without arterial phase hyperenhancement (APHE), and identify which features could predict LR-5 progression on serial Gd-EOB-DTPA-enhanced MRI follow-up. Methods: Forty-nine cirrhotic patients with 55 LR-3 and 19 LR-4 without APHE were evaluated. Observations were classified as decreased, stable or increased in category at follow-up. Observation size and LI-RADS major and ancillary features were evaluated. Results: Seventeen/fifty-five (31%) LR-3 and 8/19 (42%) LR-4 progressed to LR-5 at follow-up. Baseline LI-RADS major and ancillary features were not significantly different among LR-3 and LR-4. A diameter ≥ 10 mm significantly increased LR-5 progression risk of LR-3 (OR = 6.07; 95% CI: 0.12; 60.28]; P < .001). LR-4 with a diameter ≥ 10 mm more likely become LR-5 at follow-up (OR = 8.95; 95% CI: 0.73; 111.8; P = .083]). Conclusion: LR-3 and LR-4 without APHE were often downgraded or remained stable in category on Gd-EOB-DTPA-enhanced MRI follow-up.
year | journal | country | edition | language |
---|---|---|---|---|
2020-04-23 |